PCLKC inhibitors are a class of compounds that engage with the PCLKC protein, a notional entity within the biochemical realm, to modulate its activity. These inhibitors work by specifically targeting PCLKC and interacting with it in a way that alters its normal function within cells. The primary mechanism through which these inhibitors operate involves disrupting the protein's ability to interact with other molecules or to participate in signaling pathways, which can result in changes to cell behavior. The development of PCLKC inhibitors is rooted in a deep understanding of the protein's structure and the essential roles it plays in cellular processes.
The process of discovering and refining PCLKC inhibitors is meticulous and multifaceted. It often begins with high-throughput screening techniques, which test thousands of chemicals to identify those with inhibitory effects on PCLKC. Once promising candidates are found, a series of related compounds may be synthesized to enhance their effectiveness and selectivity, ensuring minimal off-target effects on other proteins. Advanced computational tools are employed to model the interaction between the inhibitors and PCLKC, predicting how they might bind to and affect the protein. These predictions are then validated and refined through laboratory techniques such as X-ray crystallography, which can reveal the precise manner in which the inhibitors attach to PCLKC at the atomic level. The fine-tuning of PCLKC inhibitors is critical to their effectiveness. By understanding the unique structural characteristics and active sites of PCLKC, scientists can design inhibitors that are highly specific, reducing the likelihood of cross-reactivity with other proteins. This specificity is crucial for ensuring that the desired effect on PCLKC is achieved with minimal unintended consequences. The inhibitors can thus be crafted to exhibit a variety of actions, such as reversible or irreversible binding, competitive or non-competitive inhibition, among others, depending on the structural insights obtained during research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $20.00 $62.00 $116.00 $246.00 $799.00 | 23 | |
EGTA sequesters calcium ions, which are essential for cadherin interactions. By chelating calcium, EGTA could possibly inhibit PC-LKC-mediated cell adhesion. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
IWR-1 is an inhibitor of the Wnt signaling pathway, which regulates cadherin expression. This compound could possibly inhibit PC-LKC by altering the transcription of genes related to cell adhesion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits Rho-associated protein kinase (ROCK), affecting the actin cytoskeleton and cell adhesion. This action could possibly inhibit PC-LKC's role in cell-cell junctions. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets Src family kinases, which phosphorylate cadherin-catenin complexes. This could possibly inhibit PC-LKC-mediated adhesion and signaling. | ||||||
CA-074 | 134448-10-5 | sc-202513 | 1 mg | $315.00 | ||
Ilomastat inhibits matrix metalloproteinases (MMPs), which can cleave cadherins. Inhibition by Ilomastat could possibly prevent ectodomain shedding of PC-LKC. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor; PI3K signaling is involved in cell adhesion. This inhibitor could possibly impact PC-LKC-mediated cellular interactions. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB-216763 inhibits GSK-3β, which affects β-catenin levels linked to cadherin function. This could possibly affect PC-LKC's role in cell adhesion. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is an HDAC inhibitor; HDACs regulate transcription, including of cadherin genes. This could possibly influence PC-LKC expression and function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I inhibits PKC, which regulates cadherins. This could possibly affect PC-LKC's adhesion and signaling roles. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase, which modulates cadherin-catenin complexes. This could possibly influence PC-LKC function. | ||||||